FDA hesitates on Arxxant
Regulators want an additional clinical trial for Eli Lilly’s diabetic retinopathy drug Arxxant (ruboxistaurin), the drug company said.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.